Baird lowered the firm’s price target on Zimmer Biomet (ZBH) to $115 from $130 and keeps an Outperform rating on the shares. The firm updated its model following Q1 results and telling investors to remain patient through the tariffs.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZBH:
- Cautious Hold on Zimmer Biomet Amid Mixed Performance and Strategic Adjustments
- Zimmer Biomet price target lowered to $110 from $135 at BofA
- Zimmer Biomet price target lowered to $115 from $138 at Stifel
- Cautious Outlook for Zimmer Biomet Holdings Amid Tariff Exposure and Conservative Guidance
- Zimmer Biomet Reports Q1 2025 Financial Results